
Genetic Technologies Limited GENE
Annual report 2022
added 08-30-2022
Genetic Technologies Limited Income Statement 2011-2026 | GENE
Annual Income Statement Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
9.22 B | 17.1 B | 16.6 B | 11.7 M | 19.8 M | 12.9 M | 26 M | 24.4 M | 17.4 M | 40.1 M | 57.6 M | 81.5 M |
Shares |
9.22 B | 8.54 B | 4.16 B | 4.71 M | 4.35 M | 3.79 M | 3.06 M | 1.92 M | 1.03 M | 843 K | 822 K | 723 K |
Historical Prices |
1.44 | 2.07 | 4.37 | 2.79 | 3.44 | 5.76 | 4.4 | 8.24 | 23.3 | 32.8 | 49 | 63.6 |
Net Income |
-7.13 M | -7.08 M | -6.29 M | -6.43 M | -5.46 M | -8.4 M | -8.46 M | -8.81 M | -10.1 M | -9.3 M | -5.29 M | 910 K |
Revenue |
6.79 M | 121 K | 9.86 K | 25.4 K | 189 K | 519 K | 825 K | 2.01 M | 4.56 M | 3.38 M | 3.69 M | 18.3 M |
Cost of Revenue |
- | - | - | 276 K | 300 K | 492 K | 743 K | - | - | - | - | - |
Gross Profit |
- | - | - | -251 K | -111 K | 26.1 K | 81.5 K | 1.12 M | 2.73 M | 1.43 M | 1.74 M | 16.2 M |
Interest Expense |
15.2 K | 16.3 K | 37.4 K | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | -6 M | -5.67 M | -7.55 M | -8.17 M | -9.52 M | -9.51 M | -8.75 M | -10.5 M | 1.66 M |
Operating Expenses |
- | - | - | 5.91 M | 5.87 M | 7.94 M | 8.64 M | 10.9 M | 12.6 M | 10.6 M | 12.8 M | 15.2 M |
General and Administrative Expenses |
- | - | - | 3.83 M | 3.02 M | 3.11 M | 3.53 M | 4.66 M | 4.25 M | 6.81 M | 6.88 M | 7.79 M |
All numbers in AUD currency
Quarterly Income Statement Genetic Technologies Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|
All numbers in AUD currency
The income statement is one of the three key financial reports of a company Genetic Technologies Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Agilent Technologies
A
|
$ 112.78 | 0.68 % | $ 34.3 B | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Biomerica
BMRA
|
$ 2.13 | - | $ 4.89 M | ||
|
Fulgent Genetics
FLGT
|
$ 16.31 | -0.12 % | $ 493 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
$ 74.22 | -1.99 % | $ 5.01 B | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Medpace Holdings
MEDP
|
$ 457.05 | 0.03 % | $ 13.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 242.53 | 0.28 % | $ 25.6 B | ||
|
Myriad Genetics
MYGN
|
$ 4.59 | -1.61 % | $ 425 M | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Pacific Biosciences of California
PACB
|
$ 1.37 | -1.8 % | $ 411 M | ||
|
Co-Diagnostics
CODX
|
$ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Precipio
PRPO
|
$ 26.85 | -0.3 % | $ 34.8 M | ||
|
Personalis
PSNL
|
$ 7.51 | -1.38 % | $ 445 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | ||
|
RadNet
RDNT
|
$ 59.53 | -3.58 % | $ 4.48 B | ||
|
Charles River Laboratories International
CRL
|
$ 157.49 | -0.32 % | $ 7.81 B | ||
|
IQVIA Holdings
IQV
|
$ 164.98 | -1.19 % | $ 28.4 B | ||
|
Senseonics Holdings
SENS
|
$ 6.58 | -0.6 % | $ 275 M | ||
|
Sotera Health Company
SHC
|
$ 13.78 | -0.76 % | $ 3.91 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
$ 1.21 | -17.47 % | $ 6.59 M | ||
|
National Research Corporation
NRC
|
$ 17.47 | -0.26 % | $ 391 M | ||
|
Neuronetics
STIM
|
$ 1.54 | -4.06 % | $ 102 M | ||
|
Interpace Biosciences
IDXG
|
$ 1.71 | 0.73 % | $ 7.5 M | ||
|
IDEXX Laboratories
IDXX
|
$ 572.18 | -1.09 % | $ 46 B | ||
|
Illumina
ILMN
|
$ 124.58 | 0.64 % | $ 19.8 B | ||
|
ICON Public Limited Company
ICLR
|
$ 99.8 | -0.55 % | $ 8.23 B | ||
|
Guardant Health
GH
|
$ 82.96 | -2.36 % | $ 10.4 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
$ 44.3 | -0.45 % | $ 2.65 B | ||
|
Celcuity
CELC
|
$ 100.81 | -5.57 % | $ 3.98 B | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 263.8 | -0.23 % | $ 21.9 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
ENDRA Life Sciences
NDRA
|
$ 3.41 | -2.16 % | $ 1.83 M | ||
|
NeoGenomics
NEO
|
$ 7.9 | -2.47 % | $ 1.01 B | ||
|
Natera
NTRA
|
$ 194.02 | -3.03 % | $ 19.1 B | ||
|
CareDx, Inc
CDNA
|
$ 17.35 | -1.2 % | $ 925 M | ||
|
OPKO Health
OPK
|
$ 1.14 | -1.3 % | $ 791 M |